451 related articles for article (PubMed ID: 33335029)
1. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
3. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
4. Genetically driven CD39 expression shapes human tumor-infiltrating CD8
Gallerano D; Ciminati S; Grimaldi A; Piconese S; Cammarata I; Focaccetti C; Pacella I; Accapezzato D; Lancellotti F; Sacco L; Caronna R; Melaiu O; Fruci D; D'Oria V; Manzi E; Sagnotta A; Parrino C; Coletta D; Peruzzi G; Terenzi V; Battisti A; Cassoni A; Fadda MT; Brozzetti S; Fazzi K; Grazi GL; Valentini V; Chirletti P; Polimeni A; Barnaba V; Timperi E
Int J Cancer; 2020 Nov; 147(9):2597-2610. PubMed ID: 32483858
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
6. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.
Eiva MA; Omran DK; Chacon JA; Powell DJ
Eur J Immunol; 2022 Jan; 52(1):96-108. PubMed ID: 34505280
[TBL] [Abstract][Full Text] [Related]
8. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
Front Immunol; 2020; 11():340. PubMed ID: 32174925
[TBL] [Abstract][Full Text] [Related]
10. Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.
Weimer P; Wellbrock J; Sturmheit T; Oliveira-Ferrer L; Ding Y; Menzel S; Witt M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Brauneck F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326415
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
12. PD-1 blockade-unresponsive human tumor-infiltrating CD8
Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
[TBL] [Abstract][Full Text] [Related]
14. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
15. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
16. Anti-4-1BB×PD-L1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD-1 Blockade.
Jeon SH; You G; Park J; Chung Y; Park K; Kim H; Jeon J; Kim Y; Son WC; Jeong DS; Shin EC; Lee JY; Han DH; Jung J; Park SH
Clin Cancer Res; 2024 May; ():. PubMed ID: 38743752
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
18. Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.
Tassi E; Bergamini A; Wignall J; Sant'Angelo M; Brunetto E; Balestrieri C; Redegalli M; Potenza A; Abbati D; Manfredi F; Cangi MG; Magliacane G; Scalisi F; Ruggiero E; Maffia MC; Trippitelli F; Rabaiotti E; Cioffi R; Bocciolone L; Candotti G; Candiani M; Taccagni G; Schultes B; Doglioni C; Mangili G; Bonini C
Front Immunol; 2023; 14():1212444. PubMed ID: 37868997
[TBL] [Abstract][Full Text] [Related]
19. Increased co-expression of 4-1BB with PD-1 on CD8+ tumor-infiltrating lymphocytes is associated with improved prognosis and immunotherapy response in cervical cancer.
Zhu X; Feng Y; Fan P; Dong D; Yuan J; Chang C; Wang R
Front Oncol; 2024; 14():1381381. PubMed ID: 38756662
[TBL] [Abstract][Full Text] [Related]
20. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
